Nanobiotix S.A.
NBTX
$51.50
-$3.57-6.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 128.97% | 128.21% | 326.50% | 292.10% | -158.54% |
| Total Other Revenue | 4.81% | 2.07% | -42.32% | -46.97% | -55.19% |
| Total Revenue | 139.46% | 138.43% | 202.38% | 177.99% | -149.58% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 139.46% | 138.43% | 202.38% | 177.99% | -149.58% |
| SG&A Expenses | 1.98% | -0.69% | 10.07% | 1.19% | -14.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.79% | -33.58% | -17.00% | -23.70% | -11.94% |
| Operating Income | 71.45% | 72.20% | 103.65% | 103.36% | -3,996.54% |
| Income Before Tax | 56.18% | 57.33% | 73.91% | 76.01% | -299.22% |
| Income Tax Expenses | 92.58% | 92.37% | -95.61% | -95.91% | -136.35% |
| Earnings from Continuing Operations | 56.14% | 57.29% | 74.05% | 76.14% | -294.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.14% | 57.29% | 74.05% | 76.14% | -294.83% |
| EBIT | 71.45% | 72.20% | 103.65% | 103.36% | -3,996.54% |
| EBITDA | 71.54% | 72.29% | 105.06% | 104.65% | -1,632.56% |
| EPS Basic | 56.89% | 58.02% | 74.22% | 76.30% | -223.24% |
| Normalized Basic EPS | 60.35% | 61.41% | 72.41% | 74.63% | -800.83% |
| EPS Diluted | 56.74% | 57.87% | 74.22% | 76.30% | -217.21% |
| Normalized Diluted EPS | 60.35% | 61.41% | 72.41% | 74.63% | -800.83% |
| Average Basic Shares Outstanding | 1.72% | 1.72% | 0.62% | 0.62% | 22.12% |
| Average Diluted Shares Outstanding | 1.72% | 1.72% | 0.62% | 0.62% | 22.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |